Pharma BD Deal Intelligence
Drugs from China are reshaping biotech. Track the licensing deals here. The database of cross-border China licensing deals captures Sanofi's $1.53 billion deal…
Sanofi bets on Sino Biopharm rovadicitinib in $1.5B licensing deal for first-in-class JAK/ROCK inhibitor.
Baker McKenzie advised Sino Biopharm on the up to US$1.53 billion exclusive license agreement with Sanofi for rovadicitinib, a global first-in-class oral…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Sanofi signed a global exclusive license agreement with Sino Biopharmaceutical's Chia Tai Tianqing subsidiary, announced March 4, 2026, for rovadicitinib (China brand Anxu), a first-in-class oral dual JAK/ROCK inhibitor delivering combined anti-inflammatory and anti-fibrotic effects. Sanofi pays $135M upfront plus up to $1.395B in development, regulatory and sales milestones and up to double-digit tiered royalties (up to $1.53B total) for worldwide rights to develop, manufacture and commercialize the asset. Rovadicitinib won its first China approval in February 2026 for intermediate-2/high-risk myelofibrosis (PMF/PPV-MF/PET-MF); Sanofi intends to develop it for chronic graft-versus-host disease (Phase III ongoing in China, Phase II cleared in the US), positioning it within its transplant franchise alongside Rezurock (belumosudil). The agreement's effectiveness is subject to customary closing conditions including regulatory clearances, so the transaction was signed but not yet closed as of the review.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Sino Biopharmaceutical Ltd. (this deal) | 2026 | $1.5B | 64 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2026 deals · Sanofi SA deals · Immunology deals